The virus is now active in more than 40 countries on six continents.

Public health officials’ COVID complacency has opened the door to new illnesses and devastating long-term damage.

It’s the cruelty of large numbers: Even if the actual prevalence of long Covid is much smaller than recent estimates, a small percentage of a large number is a large number.

Matt Ford has monkeypox, and he wrote this article to tell you all what it’s like. And to explain exactly why you do not want it. In Matt’s words, “This is my experience, but it boils down to this:…

‘Living with the virus’ is proving much harder than the early vaccine success suggested, says professor of immunology Danny Altmann

ONE BIG SIGH

Two days ago the CDC activated an Emergency Operations Center for our monkeypox (MPX) response

A new Canadian study has identified a potential key culprit causing so-called long COVID patients to continue experiencing breathing issues months after contracting COVID-19.

The takeover by this Omicron sub-variant is not pretty

The testing system set up by the CDC actually deters doctors from ordering a monkeypox test, and many physicians aren't familiar with the disease, resulting in too few tests and little tracking.

COVID-19 positive outpatients are at an increased risk of neurodegenerative disorders compared with individuals who tested negative for the virus, a new study presented today at the 8th European Academy of Neurology (EAN) Congress has shown.

Western experts are blinded by vested interests

We’ve laid out what’s known about the differences in the vaccines for the youngest children in the hopes it will parents make their decision.

Abnormal immune response, lingering virus, and blood clots all under investigation

The Omicron, or Pango lineage B.1.1.529, variant of SARS-CoV-2 carries multiple spike mutations with high transmissibility and partial neutralizing antibody (nAb) escape. Vaccinated individuals show protection from severe disease, often attributed to ...

Zero-COVID is possible, but few of us in the West are willing to pay the costs; the exact same reasoning applies to free speech; in both cases China-lite is the worst possible strategy.

The platform provides a space for long COVID sufferers to connect with other afflicted folks — and fight rampant misinformation.

Moderna said Wednesday that using a new version of its Covid-19 vaccine as a booster led to a superior antibody response against the Omicron variant compared to its current shot.

For nearly two years, as the Covid pandemic disrupted life around the globe, other infectious diseases were in retreat. Now the viral and bacterial nuisances are returning — and behaving in unexpected ways.

Early on, clinicians ruled out the most concerning possibility for Paxlovid rebound: that the virus was evolving resistance to the drug, a prospect that could undermine the treatment before it even had time to take off.

This month we’ve witnessed the global Avian flu outbreak, chocolates laced with salmonella, severe hepatitis of unknown cause among children, Ebola outbreak in West Africa, the first Polio case in Mozambique in 30 years, and . . . a global outbreak of monkeypox. I partnered with Dr.

AstraZeneca’s Covid-19 vaccine is facing a crisis of confidence, as one country after another temporarily suspends the vaccine’s use.

A new, large U.K. study adds to the evidence linking vaccination after Covid infection to lower odds of long Covid symptoms.

We are clearly in the middle of an infection surge in the U.S. Hospitalizations are increasing but not reflecting case acceleration, and deaths are nearing pandemic lows. The individual risk of severe disease continues to decline thanks to immunity and treatments.

There is one more hurdle: The CDC must decide whether to formally recommend the booster for this age group.

That transparency isn’t normal.

The study is small but adds to data finding benefits of mix-and-match boosting.

A House panel alleges that industry players heavily prepared a draft that became the basis for an executive order the Trump White House issued in April 2020.

The return of masking in schools is not nearly as widespread as earlier in the pandemic.

The likelihood of reporting long COVID symptoms four weeks after a first coronavirus (COVID-19) infection compatible with the Omicron BA.1 or BA.2 variants, compared with the Delta variant, using data from the COVID-19 Infection Survey.